Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04307082 | ADME Study of [14C]-Ibrexafungerp in Healthy Male Subjects | PHASE1 | COMPLETED | 6 | — | — | Dec 5, 2019 | Jun 30, 2020 | Aug 14, 2020 | 1 | United Kingdom |
Amount recovered expressed as a percentage of the dose administered
| Arm | Type | Description |
|---|---|---|
| Ibrexafungerp | EXPERIMENTAL | Oral \[14C\]-Ibrexafungerp Single Dose |
| Name | Type | Description |
|---|---|---|
| [14C]-Ibrexafungerp | DRUG | Radio-labeled Ibrexafungerp, single dose. |
Key Inclusion Criteria: * Healthy males * Age 30 to 65 years of age at the time of signing informed consent * Must be willing and able to participate in the whole study * Must provide written informed consent * Must agree to adhere to the contraception requirements Key Exclusion Criteria: * Subje...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| IQVIA Holdings Inc | IQV | 1 | PHASE3 | Olorofim, AmBisome |
| Merck & Co., Inc. | MRK | 1 | PHASE2 | Posaconazole /kg, Posaconazole PFS /kg |
| SCYNEXIS, Inc. | SCYX | 1 | — | Undisclosed |
| Innate Pharma SA Sponsored ADR | IPHA | 1 | — | Undisclosed |
| Gilead Sciences, Inc. | GILD | 1 | — | Undisclosed |